BioSpace News Archive

Vapotherm, Inc., announced that it will release financial results for the third quarter of 2023 after the close of trading on Wednesday, November 8, 2023.

Mallinckrodt plc announced that three scientific abstracts evaluating treatment with TERLIVAZ® for injection for adults with hepatorenal syndrome with rapid reduction in kidney function – including its impact on patient care, key HRS endpoints and patient comorbidity – will be presented at the American Society of Nephrology Kidney Week 2023 Scientific Meeting in Philadelphia, Pennsylvania, taking place November 2-5, 2023.

The board of directors of Eli Lilly and Company has declared a dividend for the fourth quarter of 2023 of $1.13 per share on outstanding common stock.

Merck, known as MSD outside of the United States and Canada, announced that Jannie Oosthuizen, president, Human Health U.S., is scheduled to participate in a fireside chat at the UBS BioPharma Conference on Wednesday.

ADMA Biologics, Inc. announced that it will report third quarter 2023 financial results on November 8, 2023, after the U.S. financial markets close.

PolyPid Ltd., a late-stage biopharma company aiming to improve surgical outcomes, announced that it will report its third quarter 2023 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, November 8, 2023.

Monopar Therapeutics Inc. will present data from its ongoing Phase 1b open-label, dose-escalating clinical trial of camsirubicin in patients with advanced soft tissue sarcoma later at the 2023 Connective Tissue Oncology Society Annual Meeting, which is bringing together the world’s leading sarcoma specialists.

Celcuity Inc. today announced that Brian Sullivan, Chairman, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences.

Avanos Medical, Inc. (NYSE: AVNS) today reported third quarter 2023 financial results.

cTRL Therapeutics today announced the appointment of Derrell D. Porter, M.D., as Chief Executive Officer.